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There are many studies that show biological differences between invasive ductal carcinoma (IDC) with and without nodal metastasis,
but no prognostic classification taking into consideration any biological differences between them is currently available. We previously
investigated the histological characteristics that play an important role in tumour progression of IDCs according to their nodal status,
and a new prognostic histological classification, the primary tumour–vessel tumour–nodal tumour (PVN) classification, was devised
based on the histological characteristics of IDCs with and without nodal metastasis. Multivariate analyses using the Cox proportional
hazard regression models were used to compare the ability of the PVN classification to predict tumour recurrence and death in 393
IDC patients based on the following histological classifications: (1) the pTNM classification, (2) the Nottingham Prognostic Index, (3)
the modified Nottingham Prognostic Index, and (4) the histologic grade. In IDCs without nodal metastasis, only the PVN classification
significantly increased the hazard rates (HRs) of tumour recurrence and death (Po0.05), independent of the hormone receptor
status. Similarly, in IDCs with nodal metastases, only the PVN classification significantly increased the HRs of tumour recurrence and
death (Po0.05), independent of the hormone receptor status. We conclude that the PVN prognostic histological classification is the
best classification available for IDC of the breast.
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There are many studies that show differences between the
prognostic parameters of the primary-invasive tumours of invasive
ductal carcinoma (IDC) patients with and without nodal metastasis
(Gilchrist et al, 1993; Pedersen et al, 2000; Depowski et al, 2001;
Scorilas et al, 2001), and the former show a significantly worse
prognostic course than the latter. Thus, it is necessary to accurately
predict the difference in the malignant potential of IDCs with and
without nodal metastasis from the viewpoint of neoadjuvant or
adjuvant chemotherapy for IDC patients.
We recently clearly demonstrated that the histological char-
acteristics of tumour cells in lymph vessels, blood vessels, and
lymph nodes play a very important role in tumour progression of
IDCs of the breast (Hasebe et al, 2002b, 2003a,b, 2004a). Among
these histological characteristics, we clearly identified the most
important histological characteristics predicting the outcome of
IDC patients with and without nodal metastasis (Hasebe et al,
2004b). Our studies clearly showed that the prognostic histological
characteristics of primary-invasive tumours and tumour cells in
vessels differ in IDCs without and with nodal metastasis, and that
the histological characteristics of tumours in lymph nodes play a
more important role in the outcomes of IDC patients with nodal
metastasis than those of the primary-invasive tumours or tumour
cells in vessels. These findings strongly suggest the characteristics
of IDCs with and without nodal metastasis are different. We
therefore attempted to establish separate new histological prog-
nostic classifications consisting of histological characteristics
suitable for IDC patients with and without nodal metastasis based
on a total evaluation of the histological characteristics of the
primary-invasive tumours and tumour cells in vessels and lymph
nodes.
The pTNM classification, the Nottingham Prognostic Index
(NPI), and histologic grade are the major histological prognostic
classifications currently used clinically to predict the outcome of
patients with IDC (Bloom and Richardson, 1957; Todd et al, 1987;
Elston and Ellis, 1991; Sundquist et al, 1999; Sobin and Witterkind,
2002). Nevertheless, these prognostic classifications use histologi-
cal characteristics common to both primary-invasive IDC tumours
with and without nodal metastasis, meaning that they do not take
into consideration any differences between IDCs with and without
nodal metastasis.
The purpose of this study was to establish separate prognostic
histological classifications for IDC patients with and without
nodal metastasis based on not only the histological characteristics
of the primary-invasive tumours but also of the tumour cells in
lymph vessels, blood vessels, and nodal metastatic tumours
according to hormone receptor status. The results clearly
demonstrated that the newly proposed prognostic histological
classifications are the best classifications available for IDC of the
breast.
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sMATERIALS AND METHODS
Patients
A total of 392 consecutive cases of IDC of the breast surgically
treated between July 1992 and November 1998 at the National
Cancer Center Hospital East served as the basis of this study.
Clinical information was obtained from the patients’ medical
records after complete histological examination of all of the IDCs.
All patients were Japanese women, and they ranged in age from 28
to 78 years (mean, 51 years). All had a solitary lesion. In total, 209
patients were premenopausal, and 183 were postmenopausal.
Partial mastectomy was performed in 55, modified radical
mastectomy in 313, and standard radical mastectomy in 24
patients. Axillary lymph node dissection consisting of levels I, II,
7III was carried out in all patients. None of the patients had
received radiotherapy or chemotherapy before surgery. Adjuvant
therapy was performed in 289 patients. Of the 188 IDC patients
without nodal metastasis, 88 received no adjuvant therapy, 24
received tamoxifen, 45 received CMF (cyclophosphamide, metho-
trexate, and 5-FU), AC (adriamycin and cyclophosphamide), or EC
(epirubicin and cyclophosphamide), and 31 received chemother-
apy plus tamoxifen. Of the 204 IDC patients with nodal metastases,
14 received no adjuvant therapy, 34 received tamoxifen, 51
received chemotherapy, and 105 received chemotherapy plus
tamoxifen. There were no cases of inflammatory breast cancer in
this series. Oestrogen receptors (ERs) and progesterone receptors
(PRs) in the cytosol fractions were determined by enzyme
immunoassay (Otsuka Assay Laboratory, Tokushima, Japan).
The upper cutoff values of the ER assay and PR assay were
13fmolmg
 1 protein and 10fmolmg
 1 protein, respectively.
For pathological examination, the surgically resected specimens
were fixed in 10% formalin, and multiple histological sections were
taken from each tumour for histological examination without
knowledge of the patient’s outcome. The sections were processed
routinely and embedded in paraffin.
Proposed new prognostic classifications
We attempted to establish new separate histological prognostic
classifications, called the PVN (primary tumour–vessel tumour–
nodal tumour) classifications, for IDC patients with and without
nodal metastasis. The PVN classifications for IDCs with and
without nodal metastases were devised based on the histological
characteristics of the tumour that were found to be most important
in predicting the outcome of IDC patients in the previous studies
(Hasebe et al, 2004b). The parameters of the PVN classification for
IDCs with and without nodal metastasis are listed in Tables 1 and
2. The method for assessing each parameter is described in the
previous studies (Hasebe et al, 2002b, 2003a,b, 2004a,b). In the
PVN classification for IDC without nodal metastasis (Table 1), a
score of 1 point each was given for an FF 48mm in dimension
(Hasebe et al, 2000, 2002a), lymph vessel tumour emboli with 46
apoptotic figures, lymph vessel tumour emboli 43mm distant
from the primary-invasive tumour margin, and 42 blood vessels
invaded. In the classification of IDC with nodal metastasis
(Table 2), a score of 1 point each was given for tumour necrosis
(Gilchrist et al, 1993), severe nuclear atypia of the primary-
invasive tumours, 45 lymph vessels invaded, 42 apoptotic
figures in blood vessel tumour emboli, 45 lymph nodes with
extranodal invasion, and 45 mitotic figures in nodal metastatic
tumours. A score of 0 was given for each of the above that was
absent. The total PVN scores for IDCs with and without nodal
metastasis were calculated.
Prognostic histological classifications for comparative
study
The following existing histological classifications were compared
with our proposed new classification in regard to prediction of
disease-free and overall survival: (1) pTNM (Sobin and Witterkind,
2002), (2) NPI (Todd et al, 1987; Sundquist et al, 1999), and (3) HG
(Bloom and Richardson, 1957; Elston and Ellis, 1991). The NPI
classification generally consisted of the following three groups:
Table 1 PVN classification of IDC without nodal metastasis and tumour
recurrence and death rates of PVN classifications at 5 years after the initial
operation
Parameter Score
(1) Fibrotic focus, dimension, in primary-invasive tumours
Absent/p8mmvs 48mm 0vs 1
(2) Number of apoptotic figures in lymph vessel tumour emboli
Absent/p6 vs 460 vs 1
(3) Distance of lymph vessel tumour emboli from primary-invasive tumour margin
Absent/p3mmvs 43mm 0vs 1
(4) Number of blood vessel invasion
Absent/p2 vs 420 vs 1
Total: 0–4
Tumour recurrence and death rates according to the PVN scores at 5 years from
the initial operation
Classes (scores) Cases TRR (%) MR (%)
Low (0) 109 5 (5) 1 (1)
Int (1) 54 10 (19) 5 (9)
High (2) 22 7 (32) 3 (14)
Very high (3/4) 3 3 (100) 3 (100)
Total 188 25 12
PVN¼primary tumour–vessel tumour–nodal tumour; absent¼absent for event;
IDC¼invasive ductal carcinoma; TRR¼tumour recurrence rate; MR¼mortality
rate; Int¼intermediate; 3/4¼3 and 4.
Table 2 PVN classification of IDC with nodal metastases, and tumour
recurrence and death rates of the PVN classification at 5 years after the
initial operation
Parameters Score
(1) Tumour necrosis in primary-invasive tumours
Absent vs present 0 vs 1
(2) Nuclear atypia of primary-invasive tumours
Mild/moderate vs severe 0 vs 1
(3) Number of lymph vessels invasion
Absent/p5 vs 450 vs 1
(4) Number of apoptotic figures in blood vessel tumour emboli
Absent/p2 vs 420 vs 1
(5) Number of lymph nodes with extranodal invasion
No/p5 vs 450 vs 1
(6) Number of mitotic figures of nodal metastatic tumours
N0/p5 vs 450 vs 1
Total: 0–6
Tumor recurrence and death rates according to the PVN scores at 5 years from
the initial operation
Classes (scores) Cases TRR (%) MR (%)
Low (0) 31 1 (3) 0
Int (1/2) 97 20 (21) 9 (9)
High (3) 42 23 (55) 19 (45)
Very high (4–6) 35 28 (80) 26 (74)
Total 205 72 54
PVN¼primary tumour–vessel tumour–nodal tumour; IDC¼invasive ductal
carcinoma; absent¼absent for event; TRR¼tumour recurrence rate; MR¼mortality
mortality rate; Int¼intermediate; 1/2¼1 and 2; 4–6¼4t o6 .
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slow, NPI p3.4; intermediate, 3.4oNPIp5.4; high, NPI45.4.
However, we additionally divided the intermediate NPI group into
an intermediate low group (3.4oNPIp4.4), and an intermediate
high group (4.4oNPIp5.4), and this classification was regarded as
a modified NPI and compared with the PVN classification to
predict the outcome of the IDC patients.
Outcome
Patient survival was evaluated by follow-up for a median period of
94 months, ranging in months from 61 to 136 months as of
November 2003. A total of 106 patients experienced tumour
recurrence, and 83 had died of their disease. Disease-free and
overall survival were measured from the date of surgery.
Metastasis or local recurrence was considered evidence of tumour
relapse. Only deaths due to breast cancer were considered for the
purposes of this study.
Statistical analysis
We divided each classification into four groups (IDCs without
nodal metastasis: low (score 0), intermediate (score 1), high (score
2), and very high-risk groups (scores 3 and 4) (Table 1); IDCs with
nodal metastasis: low (score 0), intermediate (scores 1 and 2), high
(score 3), and very high-risk groups (score 4–6) (Table 2), based
on significant associations with tumour recurrence or death in the
univariate analyses by the Cox proportional hazard regression
model (Cox, 1972). Survival curves were drawn following the
Kaplan–Meier method (Kaplan and Meier, 1958). In IDCs without
nodal metastasis, since the number of tumour recurrences or
deaths was relatively small, when compared according to the
hormone receptor status, the trend values of the hazard rate (HR),
95% confidence interval (CI), and the P-values for disease-free or
overall survival were evaluated using a multivariate analysis with
the Cox proportional hazard regression model. Since only five
patients with IDCs without nodal metastasis and either or both
positive for ER and PR died, a multivariate analysis could not be
performed for overall survival. In IDCs with nodal metastasis
according to hormone receptor status, since tumour recurrence
and/or death was not observed in the low-risk groups of the PVN,
NPI, modified NPI, pTNM, or HG classifications, the low- and
intermediate-risk groups were taken together as a referent category
to assess the HRs of tumour recurrence or death in the
multivariate analyses. The predictive power for disease-free and
overall survivals of each classification was evaluated by multi-
variate analysis using the Cox proportional hazard regression
model (Cox, 1972).
All analyses were performed with Statistica/Windows software
(StatSoft, Tulsa, Okla).
RESULTS
Tumour recurrence and death rates of the PVN
classification
In IDCs without nodal metastasis, the largest numbers of patients
were observed in the low-risk group, and the number of patients
belonging to each group decreased in the risk order of the
classification (Table 1). The rates of tumour recurrence or death of
IDC patients increased in the score order of the classification, and
all cases belonging to the very high-risk group showed tumour
recurrence and death by 5 years after the initial operation. The
PVN classification showed significantly short crude disease-free
and overall survival periods in the risk order of the classification
(Po0.001, Figure 1A–E).
In IDCs with nodal metastasis, the rates of tumour recurrence or
death increased in the risk order of the classification, and the
tumour recurrence of the low-risk group was observed only in one
case, and no case died of the disease (Table 2). On the contrary, the
tumour recurrence rate of the very high-risk group reached 80%,
and the tumour death rate of the very high-risk group exceeded
70%. Crude disease-free and overall survival periods of the PVN
classification were significantly shortened in the risk order of the
classification (Po0.001, Figure 1E–H).
Comparative studies of the PVN classification with pTNM,
NPI, modified NPI, and HG classifications
In IDCs without nodal metastasis and positive for ER or PR or
both, the PVN classification had the largest number of cases in the
low-risk group, compared with all the prognostic classification
systems studied, and the frequency of tumour recurrence or death
in the low-risk group was similar to that of the other prognostic
classifications (Table 3, Figure 1A and B). The frequency of tumour
recurrence or death in the very high-risk group of the PVN
classification was 100%. On the other hand, the frequencies of
tumour recurrence or death in the high-risk groups of the other
prognostic classification systems were very low. In the multivariate
analyses, the PVN classification showed a significant trend
for the HR, 95% CI, and the P-values for disease-free survival
when compared with the other prognostic classification
systems, and only the NPI classification also showed a significant
trend for the HR, 95% CI, and the P-values for disease-free survival
(Table 3).
In IDCs without nodal metastasis that were negative for both ER
and PR, the PVN classification and the pTNM classification
selected almost an equally large number of cases belonging to
the low-risk group. However, the frequency of tumour recurrence
or death in the very high-risk group of the former classification
was 100%, while no cases of tumour recurrence or death were
observed among the stage IIIB cases in the latter classification
(Table 4, Figure 1C and D). The frequencies of tumour recurrence
or death in the high-risk groups of the other prognostic
classification systems were very low, and the NPI, modified
NPI, and HG classifications could not narrow the number of
cases belonging to each risk group in the risk orders of the
classification systems. In the multivariate analyses, the PVN
classification significantly increased the trend values for the
HRs, 95% CI, and the P-values for disease-free and overall survival
when compared with other prognostic classification systems
(Table 4). On the other hand, other prognostic classification
systems failed to significantly increase the trend values for the
HRs, 95% CI, and the P-values when compared with the PVN
classification.
In IDCs with nodal metastasis and positive for ER or PR or both,
the rates of tumour recurrence or death increased according to the
risk order of the PVN classification, and the rates of tumour
recurrence and death in the very high-risk group were 72 and 62%,
respectively (Table 5, Figure 1E and F). In the pTNM classification,
the rates of tumour recurrence or death for cases classified as IIB,
IIIA, or IIIB were similar, and the rates of tumour recurrence and
death for IIIC cases were lower than those in the very high-risk
group of the PVN classification. Although the rates of tumour
recurrence or death in the NPI, modified NPI, and HG
classifications increased according to the risk order of the
classifications, the tumour recurrence and death rates in the
high-risk groups were lower than those in the very high-risk group
of the PVN classification. In addition, the NPI, modified NPI, and
HG classifications could not narrow the number of cases belonging
to each risk group in the risk orders of the classifications. In the
multivariate analyses, the PVN classification significantly in-
creased the HRs of tumour recurrence and death in the high and
PVN classification of IDCs of the breast
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Figure 1 The disease-free and the overall survival curves according to the PVN classification system in IDCs without nodal metastasis that were positive
for ER and/or PR (A and B), IDCs without nodal metastasis that were negative for both ER and PR (C and D), IDCs with nodal metastasis that were positive
for ER and/or PR (E and F), and IDCs with nodal metastasis that were negative for both ER and PR (G and H). The disease-free and overall survival curves
of each risk group in each IDC subgroups decrease according to the risk order of the classification, with the very high-risk groups in each IDC subgroup
showing the shortest disease-free and overall survival curves independent of nodal status and hormone receptor status.
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svery high-risk groups when compared with the pTNM, NPI, and
HG classifications (Table 5). On the other hand, only the pTNM
classification significantly increased the HRs of tumour recurrence
and death for the stage IIIC cases when compared with the
PVN classification, and the NPI and HG classifications failed to
increase the HRs of tumour recurrence or death when compared
with the PVN classification. In a comparative study of the PVN
classification and the modified NPI classification, although
the PVN classification failed to significantly increase the HRs
of tumour recurrence in the high risk-group, it significantly
increased the HRs of tumour death in the high and very
high-risk groups. On the other hand, the modified NPI classifica-
tion showed a marginally significant increase in the HRs of tumour
recurrence in the intermediate-high, and high-risk groups, but
failed to significantly increase the HRs of tumour death in
these groups.
In IDCs with nodal metastasis who were negative for both ER
and PR, the rates of tumour recurrence or death according to the
risk order of the PVN classification, and the rates of tumour
recurrence and death in the very high-risk group were 88 and 88%,
respectively (Table 6, Figure 1G and H). In the pTNM classifica-
tion, the rates of tumour recurrence or death in the stage IIB, IIIA,
or IIIB classifications were almost the same, and the rates of
tumour recurrence and death in the stage IIIC classification were
lower than those in the very high-risk group of the PVN
classification. Although the rates of tumour recurrence or death
in the NPI, modified NPI, or HG classifications increased
according to the risk order of the classifications, the tumour
recurrence and death rates in the high-risk groups of them were
lower than those in the very high-risk group of the PVN
classification. In addition, the pTNM, NPI, modified NPI, and
HG classifications could not narrow the number of cases belonging
to each risk group. Multivariate analyses showed that the high- and
very high-risk groups of the PVN classification significantly
increased the HRs of tumour recurrence and death when
compared with the other prognostic classification systems
(Table 6). On the contrary, no significant increases in the HRs of
tumour recurrence or death were observed in the pTNM,
NPI, modified NPI, and HG classifications in the multivariate
analyses.
Table 3 Crude disease-free and overall survival for PVN, pTNM, NPI, and HG classifications in patients with IDC without Nodal Metastasis and Positive
for ER or PR or Both
PVN PTNM
Classes Cases TRR (%) MR (%) Stages Cases TRR (%) MR (%)
Low 74 4 (5) 1 (1) I 66 5 (8) 2 (3)
Int 34 6 (18) 2 (6) IIA 49 9 (18) 2 (4)
High 12 4 (33) 1 (20) IIB 1 0 0
Very high 1 1 (100) 1 (100) IIIB 5 1 (20) 1 (20)
Total 121 15 5 Total 121 15 5
NPI Modified NPI
Classes Cases TRR (%) MR (%) Classes Cases TRR (%) MR (%)
Low 68 3 (4) 0 Low 68 3 (4) 0
Int 53 12 (23) 5 (9) Int, low 29 8 (28) 2 (7)
High 0 Int, high 24 4 (17) 3 (13)
Total 121 15 5 High 0
Total 121 15 5
HG
Grades Cases TRR (%) MR (%)
1 39 2 (5) 0
2 48 7 (15) 0
3 34 6 (18) 5 (15)
Total 121 15 5
Multivariate analyses
Classifications Disease-free survival
Trend HR/95% CI P for trend
PVN 2.6/1.5–4.7 o0.001
pTNM 1.2/0.7–1.8 0.478
PVN 2.1/1.2–3.8 0.013
NPI 3.9/1.0–14.6 0.046
PVN 2.4/1.3–4.3 0.003
Modified NPI 1.6/0.8–3.1 0.150
PVN 2.5/1.4–4.4 0.002
HG 1.4/0.7–2.8 0.396
PVN¼primary tumour–vessel tumour–nodal tumour; NPI¼Nottingham Prognostic Index; HG¼histologic grade; HR¼hazard ratio; CI¼confidence interval; TRR¼tumour
recurrence rate; MR¼mortality rate. Multivariate analyses were performed between PVN and pTNM, between PVN and NPI, and between PVN and HG.
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sDISCUSSION
The current study clearly demonstrated that the PVN classification
is the only prognostic classification that can classify IDC patients
into the four groups according to in the risk order of the
classification with significant rates of tumour recurrence or death.
In addition, only the PVN classification could select IDC patients
with the very high risk of tumour recurrence or death independent
of nodal status and hormone receptor status. Since the parameters
of the PVN classification were selected based on the precise studies
that evaluate the histological characteristics of the primary-
invasive tumours, tumours in vessels, and those in lymph nodes
(Hasebe et al, 2002b, 2003a,b, 2004a,b), they are most likely the
most suitable ones to accurately assess the true biological
malignant potential of IDCs. Therefore, we conclude that the
PVN classification is the best prognostic histological classification
available for IDCs of the breast.
The comparative studies also clearly demonstrated the merits
and demerits of the other prognostic classifications in the
prediction of the outcome of IDC patients. In IDCs without nodal
metastasis, the pTNM and HG classifications could not signifi-
cantly increase the trend values for the HRs of tumour recurrence
or death in the multivariate analyses, but a significant increase in
the trend values of the HRs of tumour recurrence was observed for
the NPI classification in multivariate analyses with the PVN
classification in IDCs positive for ER and/or PR. The pTNM
classification evaluates the malignant potential of IDCs only
according to the invasive tumour size of the primary tumours.
The HG classification evaluates the degree of tubular formation,
the degree of nuclear atypia, and the number of mitotic figures in
tumour cells, but takes no account of invasive tumour size. The
NPI classification evaluates the malignant potential of IDCs
according to the HG and invasive tumour size of the primary
invasive tumours. This strongly suggests that the NPI classification
system contains more biological information based on the tumour
histology of the primary invasive tumour cells than the pTNM
classification and more biological information on the tumour size
of the primary invasive tumours than the HG classification. Thus,
the NPI classification can more precisely assess the malignant
potential of IDCs positive for ER and/or PR than the pTNM and
HG classifications, resulting in the superiority of the former to the
latter in the prediction of the outcome of IDC patients without
nodal metastasis who were positive for ER and/or PR. However, in
IDCs negative for both ER and PR, the NPI classification failed to
Table 4 Crude disease-free and overall survival for PVN, pTNM, NPI, and HG classifications in patients with IDC without nodal metastasis and negative
for both ER and PR
PVN pTNM
Classes Cases TRR (%) MR (%) Stages Cases TRR (%) MR (%)
Low 36 2 (6) 2 (6) I 35 4 (11) 4 (11)
Int 20 6 (30) 4 (20) IIA 28 7 (25) 5 (18)
High 10 3 (30) 3 (30) IIB 3 2 (67) 2 (67)
Very high 2 2 (100) 2 (100) IIIB 2 0 0
Total 68 13 11 Total 68 13 11
NPI Modified NPI
Classes Cases TRR (%) MR (%) Classes Cases TRR (%) MR (%)
Low 17 1 (6) 1 (6) Low 17 1 (6) 1 (6)
Int 51 12 (24) 10 (20) Int, low 25 4 (16) 4 (16)
High 0 Int, high 26 8 (31) 6 (23)
Total 68 13 11 High 0
Total 68 13 11
HG
Grades Cases TRR (%) MR (%)
16 0 0
2 18 2 (11) 2 (11)
3 44 11 (25) 9 (20)
Total 68 13 11
Multivariate analyses
Classifications Disease-free survival Overall survival
Trend HR/95% CI P for trend Trend HR/95% CI P for trend
PVN 2.7/1.4–5.0 0.002 2.7/1.4–5.0 0.002
pTNM 1.1/0.6–1.8 0.818 1.0/0.5–1.9 0.971
PVN 2.5/1.3–4.6 0.003 2.5/1.3–4.7 0.004
NPI 3.1/0.4–24.7 0.289 2.4/0.3–19.2 0.421
PVN 2.6/1.4–4.9 0.003 2.6/1.4–4.9 0.003
Modified NPI 2.0/0.9–4.8 0.110 1.6/0.7–3.9 0.299
PVN 2.8/1.5–5.2 0.001 2.8/1.5–5.3 0.001
HG 3.2/0.8–12.6 0.100 2.9/0.7–11.7 0.144
PVN¼primary tumour–vessel tumour–nodal tumour; NPI¼Nottingham Prognostic Index; HG¼histologic grade; HR¼hazard ratio; CI¼confidence interval; TRR¼tumour
recurrence rate; MR¼mortality rate. Multivariate analyses were performed between PVN and pTNM, between PVN and NPI, and between PVN and HG.
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sTable 5 Crude disease-free and overall survival for PVN, pTNM, NPI, and HG classifications in patients with IDCs with nodal metastasis and positive for
ER or PR or both
PVN PTNM
Classes Cases TRR (%) MR (%) Stages Cases TRR (%) MR (%)
Low 23 2 (9) 0 IIA 26 0 0
Int 71 15 (21) 11 (15) IIB 26 7 (27) 3 (12)
High 18 9 (50) 8 (44) IIIA 30 10 (33) 8 (27)
Very high 18 13 (72) 12 (67) IIIB 16 4 (25) 4 (25)
IIIC 32 18 (56) 16 (50)
Total 130 39 31 Total 130 39 31
NPI Modified NPI
Classes Cases TRR (%) MR (%) Classes Cases TRR (%) MR (%)
Low 6 0 0 Low 6 0 0
Int 54 9 (17) 5 (9) Int, low 23 1 (4) 1 (4)
High 70 30 (43) 26 (37) Int, High 31 8 (26) 4 (13)
Total 130 39 31 High 70 30 (43) 26 (37)
Total 130 39 31
HG
Grades Cases TRR (%) MR (%)
1 20 5 (25) 3 (15)
2 66 15 (23) 12 (18)
3 44 19 (43) 16 (36)
Total 130 39 31
Multivariate analyses
Classifications Disease-free survival Overall survival
HR/95% CI P-value HR/95% CI P-value
PVN low Referent Referent
Intermediate 2.0/0.4–8.9 0.380 Referent
High 5.6/1.2–27.6 0.033 3.8/1.5–9.7 0.006
Very high 9.8/2.0–48.0 0.005 7.4/3.0–18.2 o0.001
P for trend: o0.001 P for trend: o0.001
pTNM IIA Referent Referent
IIB Referent Referent
IIIA 2.1/0.8–5.6 0.158 3.5/0.9–13.5 0.069
IIIB 1.1/0.3–4.1 0.837 2.6/0.6–12.2 0.215
IIIC 3.0/1.1–7.8 0.028 5.2/1.4–18.9 0.013
P for trend: 0.019 P for trend: 0.020
PVN low Referent Referent
Intermediate 2.0/0.4–9.9 0.352 Referent
High 5.3/1.0–28.1 0.048 3.4/1.3–9.1 0.012
Very high 11.8/2.2–64.4 0.005 8.1/3.1–21.1 o0.001
P for trend: o0.001 P for trend: o0.001
NPI low Referent Referent
Intermediate Referent Referent
High 1.6/0.7–3.9 0.289 2.4/0.8–7.2 0.109
P for trend: 0.204 P for trend: 0.200
PVN low Referent Referent
Intermediate 1.3/0.3–6.2 0.757 Referent
High 3.2/0.6–17.6 0.175 3.3/1.3–8.6 0.014
Very high 7.2/1.3–39.9 0.023 7.9/3.1–20.3 o0.001
P for trend: o0.001 P for trend: o0.001
Modified NPI low Referent Referent
Intermediate, low Referent Referent
Intermediate, high 7.1/0.8–59.0 0.071 3.4/0.4–30.7 0.271
High 7.7/0.9–65.1 0.061 5.7/0.7–45.5 0.100
P for trend: 0.075 P for trend: 0.154
PVN low Referent Referent
Intermediate 3.3/0.7–15.0 0.120 Referent
High 12.9/2.5–72.6 0.003 6.2/2.1–9.6 o0.001
Very high 32.9/6.0–182.2 o0.001 18.5/5.9–55.5 o0.001
P for trend: o0.001 P for trend: o0.001
HG 1 Referent Referent
2 0.5/0.2–1.6 0.274 0.8/0.2–3.0 0.718
3 0.4/0.1–1.3 0.129 0.5/0.1–2.2 0.375
P for trend: 0.166 P for trend: 0.232
PVN¼primary tumour–vessel tumour–nodal tumour; NPI¼Nottingham Prognostic Index; HG¼histologic grade; HR¼hazard ratio; CI¼confidence interval; TRR¼tumour
recurrence rate; MR¼mortality rate; Int¼intermediate. Multivariate analyses were performed between PVN and pTNM, between PVN and NPI, and between PVN and HG.
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sTable 6 Crude disease-free and overall survival for PVN, pTNM, NPI, and HG classifications in patients with IDCs with nodal metastasis and negative for
both ER and PR
PVN pTNM
Classes Cases TRR (%) MR (%) Stages Cases TRR (%) MR (%)
Low 8 0 0 IIA 16 4 (25) 4 (25)
Int 26 9 (35) 7 (27) IIB 17 9 (53) 7 (41)
High 24 15 (63) 14 (58) IIIA 14 6 (43) 5 (36)
Very high 17 15 (88) 15 (88) IIIB 4 2 (50) 2 (50)
IIIC 24 18 (75) 18 (75)
Total 75 39 36 Total 75 39 36
NPI Modified NPI
Classes Cases TRR (%) MR (%) Classes Cases TRR (%) MR (%)
Low 1 0 0 Low 1 0 0
Int 27 8 (30) 6 (22) Int, low 8 1 (13) 1 (13)
High 47 31 (66) 30 (64) Int, high 19 7 (37) 5 (26)
Total 75 39 36 High 47 31 (66) 30 (64)
HG Total 75 39 36
Grades Cases TRR (%) MR (%)
13 0 0
2 29 11 (38) 9 (31)
3 43 28 (65) 27 (63)
Total 75 39 36
Multivariate analyses
Classifications Disease-free survival Overall survival
HR/95% CI P-value HR/95% CI P-value
PVN low Referent Referent
Intermediate Referent Referent
High 3.5/1.4–8.7 0.007 3.9/1.4–10.8 0.009
Very high 9.1/3.3–25.3 o0.001 13.0/4.2–39.5 o0.001
P for trend: o0.001 P for trend: o0.001
pTNM IIA Referent Referent
IIB 2.0/0.6–6.5 0.273 1.2/0.3–4.2 0.822
IIIA 0.9/0.2–3.5 0.896 0.6/0.1–2.4 0.458
IIIB 0.8/0.4–4.9 0.817 1.3/1.4–10.8 0.652
IIIC 1.4/0.4–4.9 0.569 1.3/0.4–4.7 0.652
P for trend: 0.949 P for trend: 0.486
PVN low Referent Referent
Intermediate Referent Referent
High 3.1/1.3–7.6 0.014 3.3/1.3–8.8 0.017
Very high 7.5/2.7–20.1 o0.001 17.6/3.4–29.3 o0.001
P for trend: o0.001 P for trend: o0.001
NPI low Referent Referent
Intermediate Referent Referent
High 1.4/0.6–3.5 0.488 1.7/0.6–4.6 0.324
P for trend: 0.605 P for trend: 0.414
PVN low Referent Referent
Intermediate Referent Referent
High 2.7/1.1–6.5 0.028 3.1/1.2–8.2 0.026
Very high 6.8/2.6–18.1 o0.001 9.4/3.2–27.6 o0.001
P for trend: o0.001 P for trend: o0.001
Modified NPI low Referent Referent
Intermediate, low Referent Referent
Intermediate, high 2.9/0.3–24.2 0.335 1.9/0.2–16.9 0.578
High 3.4/0.4–28.1 0.261 2.8/0.3–24.2 0.348
P for trend: 0.453 P for trend: 0.403
PVN low Referent Referent
Intermediate Referent Referent
High 3.2/1.4–7.4 0.008 3.6/1.4–9.2 0.007
Very high 7.5/2.9–18.6 o0.001 10.7/4.0–29.6 o0.001
P for trend: o0.001 P for trend: o0.001
HG 1 Referent Referent
2 Referent Referent
3 1.5/0.7–3.2 0.334 1.5/0.7–3.5 0.304
P for trend: 0.394 P for trend: 0.359
PVN¼primary tumour–vessel tumour–nodal tumour; NPI¼Nottingham Prognostic Index; HG¼histologic grade; HR¼hazard ratio; CI¼confidence interval; TRR¼tumour
recurrence rate; MR¼mortality rate; Int¼intermediate. Multivariate analyses were performed between PVN and pTNM, between PVN and NPI, and between PVN and HG.
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recurrence and death in the multivariate analyses with the PVN
classification. Since IDCs that are negative for both ER and PR
have a much higher malignant potential than IDCs that are positive
for ER and/or PR, the NPI classification does not maintain its
prognostic predictive power when compared with the PVN
classification. In addition, this study clearly demonstrated that
the modification of the NPI classification was of no benefit to
accurate prediction of tumour recurrence or death in patients with
IDCs without nodal metastasis.
In IDCs with nodal metastasis, the comparative studies with the
PVN classification clearly demonstrated that the NPI, modified
NPI, and HG classification were no use in the prediction of the
outcome of IDC patients in the multivariate analyses, but in IDCs
that are positive for ER and/or PR the pTNM classification showed
significant trend P-values for tumour recurrence and death, and
especially in stage IIIC cases a significant increase was seen in the
HRs of tumour recurrence and death in the multivariate analyses.
The HG classification ignores the nodal status of IDCs. The NPI
and modified NPI classifications assess nodal status according to
the number of nodal metastases: score 1, no nodal metastasis;
score 2, one to three nodal metastases; and score 3, four or more
nodal metastases. Although the pTNM classification also assesses
nodal status according to the number of nodal metastases, the
stage IIIC IDCs consist of IDCs with 10 or more nodal metastases,
independent of their invasive tumour size. Thus, the assessment of
10 or more nodal metastases in the pTNM classification is
probably very important for accurately predicting the outcome of
patients with IDCs with nodal metastasis that are positive for ER
and/or PR. The pTNM evaluations of stage IIB, IIIA, and IIIB cases
failed to increase the HRs of tumour recurrence or death in the
multivariate analyses, and these stages exhibited similar rates of
tumour recurrence or death in IDCs with nodal metastases that are
positive for ER and/or PR. In addition, the NPI and modified NPI
node classifications did not improve the accurate prediction of
tumour recurrence or death in patients with nodal metastasis who
were positive for ER and/or PR. Therefore, the N1 and N2
categories of the pTNM classification probably have no effect on
the accurate prediction of the outcome of IDC patients with nodal
metastases. However, this study clearly demonstrated that in IDCs
negative for both ER and PR, the stage IIIC of the pTNM
classification failed to maintain its predictive prognostic power,
when compared with the PVN classification. Based on these
findings, the histological characteristics of the T and N categories
of the pTNM classification should be improved, since the pTNM
classification is the global prognostic classification for patients
with IDC of the breast.
In conclusion, the current study clearly demonstrated that the
PVN classification is by far the best histological classification for
predicting the outcome of patients with IDC of the breast. Indeed,
the methodology for determining the PVN classification may be
more complex than those other existing classification systems, but
the methods that evaluate the parameters of the PVN classification
have been reported in our previous studies (Hasebe et al, 2002b,
2003a,b, 2004a,b), as well as other previous studies (Donegan et al,
1993; Gilchrist et al, 1993; De Jong et al, 2000). We confirmed the
prognostic significance of the presence of tumour necrosis, the
presence of apoptotic figures in the tumour cells, and the presence
of extranodal invasion in our previous study (Hasebe et al, 2004b).
In addition, Colpaert et al (2001) confirmed the prognostic
significance of the presence of a fibrotic focus in node-negative
IDCs. In the field of medical research, technology is developing
daily, enabling many new important findings in the area of cancer
research. Consequently, new methods should not only include
primary tumour histology but also the histology of tumour in
vessels and lymph nodes to accurately assess the true malignant
potential of IDCs. Since the PVN classification provides patholo-
gists with more precise information on the malignant potential of
IDCs than other prognostic classification systems, pathologists
should make efforts to assess the true malignant potential of IDCs
using the criteria of the PVN classification.
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